T2 Biosystems Statistics
Total Valuation
T2 Biosystems has a market cap or net worth of $77.91 million. The enterprise value is $120.64 million.
| Market Cap | 77.91M |
| Enterprise Value | 120.64M |
Important Dates
The next estimated earnings date is Monday, August 5, 2024, after market close.
| Earnings Date | Aug 5, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
T2 Biosystems has 15.37 million shares outstanding. The number of shares has increased by 3,637.03% in one year.
| Shares Outstanding | 15.37M |
| Shares Change (YoY) | +3,637.03% |
| Shares Change (QoQ) | +95.20% |
| Owned by Insiders (%) | 2.42% |
| Owned by Institutions (%) | 70.75% |
| Float | n/a |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 10.86 |
| Forward PS | 5.97 |
| PB Ratio | n/a |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 16.81 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.28
| Current Ratio | 0.28 |
| Quick Ratio | 0.15 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -8.13 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -130.50% |
| Return on Capital (ROIC) | -414.34% |
| Revenue Per Employee | $63,504 |
| Profits Per Employee | -$403,947 |
| Employee Count | 113 |
| Asset Turnover | 0.21 |
| Inventory Turnover | 3.24 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -50.39% in the last 52 weeks. The beta is 0.14, so T2 Biosystems's price volatility has been lower than the market average.
| Beta (5Y) | 0.14 |
| 52-Week Price Change | -50.39% |
| 50-Day Moving Average | 5.07 |
| 200-Day Moving Average | 5.39 |
| Relative Strength Index (RSI) | 48.00 |
| Average Volume (20 Days) | 136,023 |
Short Selling Information
The latest short interest is 417,094, so 2.71% of the outstanding shares have been sold short.
| Short Interest | 417,094 |
| Short Previous Month | 315,982 |
| Short % of Shares Out | 2.71% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 2.43 |
Income Statement
In the last 12 months, T2 Biosystems had revenue of $7.18 million and -$45.65 million in losses. Loss per share was -$11.51.
| Revenue | 7.18M |
| Gross Profit | -8.39M |
| Operating Income | -48.58M |
| Pretax Income | -45.65M |
| Net Income | -45.65M |
| EBITDA | -38.59M |
| EBIT | -40.65M |
| Loss Per Share | -$11.51 |
Balance Sheet
The company has $6.76 million in cash and $49.50 million in debt, giving a net cash position of -$42.74 million or -$2.78 per share.
| Cash & Cash Equivalents | 6.76M |
| Total Debt | 49.50M |
| Net Cash | -42.74M |
| Net Cash Per Share | -$2.78 |
| Equity (Book Value) | -37.77M |
| Book Value Per Share | -2.46 |
| Working Capital | -40.70M |
Cash Flow
In the last 12 months, operating cash flow was -$46.88 million and capital expenditures -$72,000, giving a free cash flow of -$46.95 million.
| Operating Cash Flow | -46.88M |
| Capital Expenditures | -72,000 |
| Free Cash Flow | -46.95M |
| FCF Per Share | -$9.22 |
Margins
Gross margin is -116.97%, with operating and profit margins of -676.94% and -636.09%.
| Gross Margin | -116.97% |
| Operating Margin | -676.94% |
| Pretax Margin | -636.09% |
| Profit Margin | -636.09% |
| EBITDA Margin | -537.76% |
| EBIT Margin | -566.42% |
| FCF Margin | -654.28% |
Dividends & Yields
T2 Biosystems does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -3,637.03% |
| Shareholder Yield | -3,637.03% |
| Earnings Yield | -58.59% |
| FCF Yield | -60.27% |
Analyst Forecast
The average price target for T2 Biosystems is $5.00, which is -1.38% lower than the current price. The consensus rating is "Hold".
| Price Target | $5.00 |
| Price Target Difference | -1.38% |
| Analyst Consensus | Hold |
| Analyst Count | 2 |
| Revenue Growth Forecast (5Y) | 53.96% |
| EPS Growth Forecast (5Y) | -54.42% |
Stock Splits
The last stock split was on October 13, 2023. It was a reverse split with a ratio of 1:100.
| Last Split Date | Oct 13, 2023 |
| Split Type | Reverse |
| Split Ratio | 1:100 |
Scores
T2 Biosystems has an Altman Z-Score of -40.16 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -40.16 |
| Piotroski F-Score | 1 |